Chart, page-691

@Vlado, agree on this one. I cannot see much change to the SP in the absence of further expansion of the Htert testing distribution networks and an announcement relating to the approval of the Bard1 test kit. I think that it's an absolute certainty that there will be senior management changes post merger - but these should not affect the SP as I think most SH's have assumed this will happen and it will be for the better. I believe that the main pivotal announcement that will influence the SP is related to the initial approval for sale of the BD1 test kits. This is the main pivot point for the SP bouncing around 3.0-3.5 cents or thereabouts but the breakout should be related to the approval of the BD1 "kit" for commercialisation" and subsequent sale. The advantage of the BD1 kit is that the merged company already has many distribution networks set up and flowing via the Htert test and these could provide leverage for sales of the BD1 kit....anyway we must wait....hopefully the news comes prior to the end of 2020 or early 2021...either way patience is a virtue!